Core Insights - Matador Resources Company (MTDR) is scheduled to report its third-quarter 2025 results on October 21, after market close [1] Earnings Performance - In the previous quarter, Matador reported adjusted earnings of $1.53 per share, exceeding the Zacks Consensus Estimate of $1.29, primarily due to increased total production volumes [2] - The company has consistently surpassed the Zacks Consensus Estimate in the last four quarters, with an average surprise of 11.85% [2] - The Zacks Consensus Estimate for third-quarter earnings per share is $1.26, reflecting a 31.8% decline from the prior year's reported figure [2] Revenue Expectations - The Zacks Consensus Estimate for revenues stands at $902.3 million, indicating a 0.28% increase from the year-ago figure [3] Production Factors - Matador is expected to maintain stable performance in Q3, supported by its oil-rich acreages in premier shale basins, including the Delaware Basin and Eagle Ford shale play [4] - Oil production is anticipated to have grown approximately 17.5% year over year, contributing positively to revenues and profitability [4] Pricing and Margin Pressure - The company is likely to face margin pressure due to declining commodity prices, with average West Texas Intermediate spot prices for July, August, and September at $68.39, $64.86, and $64 per barrel, respectively, compared to higher prices in the same period last year [5] - The significant drop in average oil prices during the quarter may negatively impact upstream profitability despite increased production levels [5] Earnings Outlook - Current analysis does not indicate an earnings beat for Matador Resources, with an Earnings ESP of -6.1% [7] - Mixed estimate revisions and weaker pricing trends suggest a challenging quarterly outlook for the company [8] Zacks Rank - Matador Resources currently holds a Zacks Rank of 4 (Sell) [9]

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Prudential (PRU) , which belongs to the Zacks Insurance - Multi line industry.When looking at the last two reports, this financial services company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 7.01%, on average, in the last two quarters.For the most recent quarter, Prudential was expected to post earnings ...

Core Viewpoint - Epam (EPAM) has consistently beaten earnings estimates and is well-positioned for future earnings reports, particularly with a recent average surprise of 6.15% over the last two quarters [1][2]. Earnings Performance - For the last reported quarter, Epam achieved earnings of $2.77 per share, surpassing the Zacks Consensus Estimate of $2.61 per share, resulting in a surprise of 6.13% [2]. - In the previous quarter, the company was expected to report earnings of $2.27 per share but delivered $2.41 per share, yielding a surprise of 6.17% [2]. Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Epam, with a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of an earnings beat [5]. - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]. Analyst Sentiment - Epam currently has an Earnings ESP of +0.52%, suggesting that analysts have recently become more optimistic about the company's earnings prospects [8]. - The combination of a positive Earnings ESP and a Zacks Rank 3 indicates a potential for another earnings beat in the upcoming report [8]. Upcoming Earnings Report - The next earnings report for Epam is expected to be released on November 6, 2025 [8].

Core Viewpoint - Westinghouse Air Brake Technologies (WAB) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Company Performance - WAB has a solid track record of surpassing earnings estimates, particularly in the last two quarters, with an average surprise of 8.78% [2]. - In the most recent quarter, WAB reported earnings of $2.27 per share against an expectation of $2.18, resulting in a surprise of 4.13%. In the previous quarter, the company reported $2.28 per share compared to an estimate of $2.01, achieving a surprise of 13.43% [3]. Earnings Estimates - Recent estimates for WAB have been trending upward, with a positive Zacks Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [6]. - The current Earnings ESP for WAB is +1.32%, reflecting increased analyst optimism regarding its near-term earnings potential. Coupled with a Zacks Rank of 2 (Buy), this suggests a high probability of another earnings beat [9]. Predictive Metrics - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced positive surprises nearly 70% of the time, indicating a strong correlation between these metrics and earnings performance [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate being more reflective of recent analyst revisions [8].

Core Viewpoint - Illinois Tool Works (ITW) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a solid history of performance in this regard [1][5]. Group 1: Earnings Performance - Illinois Tool Works has a strong track record of exceeding earnings estimates, particularly in the last two quarters, with an average surprise of 1.25% [2]. - In the last reported quarter, the company achieved earnings of $2.58 per share, surpassing the Zacks Consensus Estimate of $2.56 per share, resulting in a surprise of 0.78% [3]. - For the previous quarter, ITW was expected to report earnings of $2.34 per share but delivered $2.38 per share, yielding a surprise of 1.71% [3]. Group 2: Earnings Estimates and Predictions - Recent changes in earnings estimates for Illinois Tool Works have been favorable, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8]. - The current Earnings ESP for Illinois Tool Works is +0.84%, suggesting that analysts have recently become more optimistic about the company's earnings prospects [8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a high probability of another earnings beat, with historical data showing that such combinations lead to positive surprises nearly 70% of the time [6][8].

Core Insights - Kiniksa Pharmaceuticals International, plc (KNSA) has a strong history of exceeding earnings estimates and is well-positioned for future earnings beats [1][2]. Earnings Performance - The company has achieved an average surprise of 238.89% over the past two quarters, indicating a consistent ability to outperform expectations [2]. - In the most recent quarter, Kiniksa reported earnings of $0.23 per share against an expectation of $0.18, resulting in a surprise of 27.78%. In the previous quarter, the earnings were $0.11 per share compared to an estimate of $0.02, leading to a surprise of 450.00% [3]. Earnings Estimates and Predictions - Estimates for Kiniksa have been trending upward, supported by its history of earnings surprises. The stock currently has a positive Zacks Earnings ESP of +8.95%, suggesting analysts are optimistic about its earnings prospects [6][9]. - The combination of a positive Earnings ESP and a Zacks Rank of 1 (Strong Buy) indicates a high likelihood of another earnings beat [9]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [8].

Core Insights - Interpublic Group (IPG) has consistently beaten earnings estimates, particularly in the last two quarters with an average surprise of 23.18% [1][5] - For the most recent quarter, Interpublic reported earnings of $0.75 per share, exceeding the expected $0.55 per share, resulting in a surprise of 36.36% [2] - The previous quarter also saw a positive surprise, with actual earnings of $0.33 per share against an estimate of $0.30 per share, marking a 10.00% surprise [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Interpublic, with a positive Earnings ESP of +6.13%, indicating bullish sentiment among analysts regarding the company's earnings prospects [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that such combinations lead to positive surprises nearly 70% of the time [6][8] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which are often more accurate [7] Importance of Earnings ESP - Monitoring a company's Earnings ESP before quarterly releases is crucial for increasing the odds of successful investment decisions [10] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [8] - Many companies can still beat consensus EPS estimates, and stock performance may not solely depend on meeting these estimates [9]

Core Insights - Core Laboratories Inc. (CLB) is expected to report third-quarter 2025 results on October 22, with a consensus estimate of 19 cents per share in profit and revenues of $127.5 million [1][7] Q2 Performance Highlights - In the last reported quarter, CLB's adjusted earnings were 19 cents per share, exceeding the consensus estimate by one cent, while operating revenues reached $130.2 million, surpassing the estimate of $128 million [2] - The positive performance was attributed to a rebound in maritime movement and crude oil trading, along with laboratory assay services [2] Earnings Surprise History - CLB has missed the Zacks Consensus Estimate in two of the last four quarters, met expectations in one, and exceeded them in another, resulting in an average negative surprise of 1.4% [3] - The consensus estimate for Q3 2025 earnings has been revised upward by 5.5% recently, but indicates a 24% year-over-year decline, while revenue estimates show a decline of about 5.1% from the previous year [3] Factors Influencing Q3 Performance - A rebound in laboratory services related to crude oil assay is anticipated, as trading patterns adjust post-sanctions [4] - The company aims to execute strategic objectives by launching new products and services in key markets while maintaining operational efficiency [4] - International oil and gas projects are expected to remain stable despite crude oil price volatility, particularly in regions like South Atlantic, North and West Africa, Norway, the Middle East, and parts of Asia Pacific [4] Revenue Challenges - CLB's revenues are projected to decline in Q3, with estimates down from $134.4 million in the previous year [5] - The Reservoir Description segment is expected to see flat revenues due to geopolitical conflicts and volatile commodity prices, while the Production Enhancement segment anticipates a lower U.S. frac spread count [5] Earnings Prediction Model - The earnings prediction model suggests a potential earnings beat for CLB, supported by a positive Earnings ESP of +5.26% and a Zacks Rank of 3 [6][8]

Core Viewpoint - RTX Corporation is expected to report its third-quarter 2025 results on October 21, with a prior earnings surprise of 7.59% in the last quarter [1] Factors Influencing Q3 Results - Rising aftermarket demand for commercial aircraft due to increased flight hours and growth in domestic and international aviation traffic is likely to enhance RTX's commercial aftermarket sales [2] - Increased commercial air passenger travel rates are expected to boost demand for commercial jet engines, positively impacting RTX's original equipment manufacturer (OEM) sales, particularly for GTF units [3] - Strong sales momentum in both commercial OEM and aftermarket channels is anticipated to benefit the Pratt & Whitney and Collins Aerospace segments [4] - Solid sales of military engines for programs like the F-35 are expected to contribute positively to Pratt & Whitney's performance [4] - Higher sales volume for integrated air and missile defense systems, driven by geopolitical tensions, is likely to enhance revenues for the Raytheon unit [5] Financial Expectations - The Zacks Consensus Estimate for earnings is $1.42 per share, reflecting a year-over-year decline of 2.1%, while revenues are estimated at $21.48 billion, indicating a year-over-year increase of 6.9% [8] - Despite higher sales volume, the impact of increased tariffs may offset some gains, although cash flow is expected to improve following recovery from prior disruptions [6][10] Earnings Prediction - The company's Earnings ESP is +1.53%, suggesting a strong likelihood of an earnings beat, supported by a Zacks Rank of 3 [11][12]

Core Insights - Boston Scientific (BSX) is set to report its third-quarter 2025 results on October 22, with expectations of strong performance based on previous earnings surpassing estimates [1][8] Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for BSX's Q3 2025 revenues is $4.97 billion, reflecting an 18.1% increase from the same quarter last year [2] - The consensus estimate for earnings per share (EPS) is 71 cents, indicating a 12.7% growth compared to the prior year's quarter [2][3] Group 2: Performance Drivers - The MedSurg division is expected to maintain solid sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is anticipated to benefit from core franchises and the expanded indication for Rezum, alongside progress from the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends in Deep Brain Stimulation continuing into Q3 [6] - The Cardiovascular segment is projected to perform well, with strong contributions from the Interventional Cardiology Therapies unit and the completion of the SoniVie acquisition [8][9] - The Peripheral Interventions unit is expected to show strong performance, bolstered by recent acquisitions and growth in both arterial and venous product lines [12] Group 3: Market Position and Trends - The MedSurg revenues are estimated at $1.70 billion, suggesting a 15% year-over-year increase [7] - Cardiovascular revenues are expected to improve by 19.6% year over year to $3.27 billion [13] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook [15]